Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin Formulations: Types and Delivery01:27

Insulin Formulations: Types and Delivery

165
Insulin preparations are categorized by their duration of action into short-acting and long-acting types. Two strategies are used to modify insulin's absorption and pharmacokinetic profile: slowing the absorption post-subcutaneous injection, or altering human insulin's amino acid sequence or protein structure. These changes retain the insulin's ability to bind to the insulin receptor, but alter its behavior in solution or after injection.
Short-acting insulins are divided into...
165
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

142
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
142
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

136
Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively...
136
Dipeptidyl Peptidase 4 Inhibitors01:23

Dipeptidyl Peptidase 4 Inhibitors

166
Dipeptidyl peptidase 4 (DPP-4) is a serine protease widely distributed in the body. It's involved in the inactivation of GLP-1 and GIP hormones, which are crucial for insulin regulation. DPP-4 inhibitors, such as sitagliptin (Januvia), saxagliptin (Onglyza), linagliptin (Tradjenta), alogliptin (Nesina), and vildagliptin (Galvus), help increase the proportion of active GLP-1, enhancing insulin secretion. These inhibitors work by competitively binding to DPP-4. This binding causes a...
166

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Ultrabright PCNs@Coumarin 6-Enhanced Wireless Lateral Flow Immunoassay Platform for Ultrasensitive Detection of <i>Porphyromonas gingivalis</i>.

ACS applied materials & interfaces·2026
Same author

Tumor heterogeneity: development, mechanisms, and therapeutic implications.

Signal transduction and targeted therapy·2026
Same author

Moderate-temperature DNA cleavage activity of TtAgo activated by dCTP/TthSSB for one-step isothermal microRNAs detection.

Nature communications·2026
Same author

A Pocketed Immunoblotting Disc for Field-Deployable Profiling of Multiantibody Spectrum.

ACS nano·2026
Same author

High-fidelity molecular decoding through tile-guided in situ self-assembly.

Science advances·2026
Same author

Flexible Dual-Apt Scaffolds Reveal gPD-L1-sEVs in Breast Cancer.

Analytical chemistry·2026

Related Experiment Video

Updated: Jun 3, 2025

An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
10:28

An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart

Published on: June 7, 2015

17.3K

Convertible Hydrogel Injection Sequentially Regulates Diabetic Periodontitis.

Jinmin Zhou1, Houxuan Li1, Shuhong Li1

  • 1College of Stomatology, Chongqing Key Laboratory of Oral Diseases, Chongqing Municipal Key Laboratory of Oral Biomedical Engineering of Higher Education, Chongqing Medical University, Chongqing 401147, China.

ACS Biomaterials Science & Engineering
|January 10, 2025
PubMed
Summary

This study developed a novel hydrogel system (TOOTH) for diabetic periodontitis treatment. It sequentially releases anti-inflammatory agents and growth factors to reduce bone loss and promote healing.

Keywords:
alveolar bone regenerationdiabetic periodontitishydrogelinflammationsequential release

More Related Videos

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

7.7K
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
06:06

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Published on: May 9, 2022

2.4K

Related Experiment Videos

Last Updated: Jun 3, 2025

An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart
10:28

An Injectable and Drug-loaded Supramolecular Hydrogel for Local Catheter Injection into the Pig Heart

Published on: June 7, 2015

17.3K
Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications
09:39

Injectable Supramolecular Polymer-Nanoparticle Hydrogels for Cell and Drug Delivery Applications

Published on: February 7, 2021

7.7K
Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease
06:06

Adjunctive Diode Laser Therapy and Probiotic Lactobacillus Therapy in the Treatment of Periodontitis and Peri-Implant Disease

Published on: May 9, 2022

2.4K

Area of Science:

  • Biomaterials Science
  • Periodontology
  • Regenerative Medicine

Background:

  • Diabetes mellitus exacerbates periodontitis through increased reactive oxygen species (ROS), leading to significant periodontal bone loss.
  • Effective treatment requires simultaneous inflammation reduction and alveolar bone regeneration, ideally through an orderly, non-interfering therapeutic approach.

Purpose of the Study:

  • To develop a sequential sustained release system for diabetic periodontal therapy.
  • To create a dual-drug delivery system capable of reducing inflammation and promoting bone regeneration in a controlled manner.

Main Methods:

  • Construction of a zeolitic imidazolate framework-8 (ZIF-8)-modified chitosan thermosensitive hydrogel (TOOTH).
  • Sequential loading and release of chemically modified tetracycline-3 (CMT-3) for ROS elimination and platelet-derived growth factor-BB (PDGF-BB) for osteogenesis.
  • Regulation of release intervals by controlling ZIF-8 particle size.

Main Results:

  • The TOOTH system demonstrated sequential release of CMT-3 followed by PDGF-BB under specific microenvironmental conditions.
  • In vitro and in vivo studies confirmed the biocompatibility and favorable therapeutic effects of TOOTH in treating diabetic periodontitis.
  • Controlled release effectively reduced inflammation and promoted periodontal tissue regeneration.

Conclusions:

  • The developed TOOTH system offers a promising strategy for sequential, controlled drug delivery in diabetic periodontitis.
  • This approach facilitates both inflammation management and alveolar bone regeneration, showing potential for clinical translation.